What is the controversy with drospirenone? Exploring the risks, legal battles, and patient impacts
•
4 min read
In 2012, the U.S. Food and Drug Administration (FDA) concluded that drospirenone-containing birth control pills may be associated with a higher risk for blood clots than other oral contraceptives, putting a spotlight on the controversy with drospirenone. This announcement and the subsequent safety labeling changes followed years of conflicting study results, legal actions, and public concern regarding the safety of these widely used medications.